Among older women with and without breast and ovarian cancers, testing for the BRCA gene dropped precipitously between 2008 and 2018.
Among older women with and without breast cancer and ovarian cancer, testing for the BRCA gene dropped precipitously between 2008 and 2018, according to a study published in JAMA Network Open.
Results from testing for BRCA1/2 pathogenic variants help to inform the treatment and prevention of related cancers, with positive findings indicating higher risk, but changing testing criteria likely mean fewer women know these results. The present study investigated the impact of these changes.
A chief finding was the greater likelihood of a BRCA-positive result among women who were non-Hispanic Black (adjusted odds ratio [aOR], 1.52; 95% CI, 1.04-2.22), living in the West (aOR, 2.67; 95% CI, 1.63-4.49) or South (aOR, 1.80; 95% CI, 1.14-2.86) regions of the United States, and living in areas with few college graduates (aOR, 1.54; 95% CI, 1.10-2.17), as well as those without a personal history of breast or ovarian cancer (aOR, 1.30; 95% CI, 1.12-1.50).
“The current study evaluates how the rate of documented positive results for BRCA testing changed over time and also evaluates the association between clinical and demographic characteristics and positive test results among US women 65 years of age or older,” the authors noted.
The study population of 5533 women, with a mean age of 68.1 (95% CI, 67.9-68.4) years, were culled from Optum’s Claims-Clinical data set. All received BRCA test results between January 1, 2008, and March 31, 2018. The primary outcome was percentage change in positive BRCA results and how that was affected by race/ethnicity, region of residence, income, educational level, and personal history of breast or ovarian cancer.
Analyses found:
Drops in positive findings were also soon over the 10-year period in the Midwest and Northeast regions, while in the West they increased.
During the study period, most of the women tested were non-Hispanic White (84.6%, n = 4679) and from the Midwest (34.6%; n = 1915). The Optum database their data came from represents more than 91 million lives across all states, and race/ethnicity were self-reported.
“The significantly decreasing rate of positive BRCA test results is evident among women 65 years of age or older, which may be partly explained by loosening of testing criteria during the evaluated time range,” they concluded. “However, socioeconomic and regional disparities were identified and persisted in testing use.”
Future studies should investigate their findings compared with those of women younger than 65, the authors recommended.
Reference
Fangjian G, School M, Fuchs EL, Wong R, Yong-Fang K, Berenson AB. Trends in positive BRCA test results among older women in the United States, 2008-2018. JAMA Netw Open. Published online November 5, 2020. doi:10.1001/jamanetworkopen.2020.24358
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More